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Mohan Doss has provided us with an interesting interpre-
tation of our study investigating cancer risks among young
people undergoing cardiac catheterization procedures
[1, 2]. As in previous correspondence [3], Doss adjusts
expected cancer incidence figures to demonstrate appar-
ently reduced standardised incidence ratios (SIR) for pop-
ulations exposed to radiation.
We have a number of concerns with this approach.
Firstly, Doss has based calculations on the figures pre-
sented in Table 3, in which no exclusion period was
applied, i.e. observed/expected cases accrue immediately
after the date of the first recorded procedure. When
assessing the impact of radiation exposure, only follow-up
after an exclusion period of 5 years (2 for
leukaemia/lymphoma) is appropriate.
Secondly, the fact that cancer incidence among young
people with congenital heart disease (CHD) is raised
compared to the general population is well known and was
part of the justification for the study. As we stated in the
introduction to our paper, increased cancer incidence may
be due to a number of factors, including genetic predis-
position, immunosuppression and radiation exposure. No
study has ever managed to isolate the relative contribution
of these separate risk factors. There are, therefore, no data
available from which to determine true ‘background’ rates
among individuals with CHD. This includes the study by
Lee et al. [4] from which Doss obtains the factor of 1.45
used to adjust expected cancer incidence figures. In par-
ticular, Lee et al. do not exclude patients with radiation
exposure nor censor transplant recipients. Furthermore,
given the variation in both CHD rates [5] and cancer
incidence [6] between countries, the use of data from
Taiwan to adjust background figures representing the UK,
Canada and Israel is likely unreliable. It is also unclear why
Doss has picked the SIR reported by Lee et al., as opposed
to other, more modestly raised SIR figures representing
populations with CHD (e.g. those reported by Bjørge et al.
[7]).
Our conclusion that radiation exposure may still con-
tribute to higher cancer rates among children with CHD
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was partly based on an internal dose response analysis, in
addition to calculation of SIR. While imprecise, the excess
elevated risk (ERR) per mGy for lympho-haematological
neoplasia of 0.018 (95% CI: -0.002, 0.096) is suggestive of
a small risk due to radiation exposure. Furthermore, we
must again emphasise that follow-up times were insuffi-
cient to allow conclusions to be drawn on cancer incidence
for the most heavily irradiated organs, including the lungs
and breasts.
While Doss is correct in stating that leukaemia inci-
dence is higher among individuals with Down syndrome,
the incompleteness of information on prevalence of this
condition in our cohort prevented us from formal analysis
of the potential for confounding. Doss states that ‘‘all the
four leukemia cases [….] were in patients with Down’s
syndrome’’. This is incorrect, although our phrasing could
have been clearer. We merely stated that all four cancer
cases developing among individuals with Down syndrome
were leukaemia. In fact only one of these diseases devel-
oped more than 2 years following the first procedure, thus
contributing to dose response analysis.
In summary, while we appreciate Dr Doss’s interest in
our study, we feel that the methods used to adjust our SIR
figures are inappropriate and we are unconvinced of the
implied suggestion that radiation exposure in this patient
group may be reducing cancer risks via a hormesis
mechanism.
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